1. Role of the Plasma Membrane Transporter of Organic Cations OCT1 and Its Genetic Variants in Modern Liver Pharmacology
   Elisa Lozano et al, 2013, BioMed Research International CrossRef
2. The Impacts ofSLC22A1rs594709 andSLC47A1rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients
   Di Xiao et al, 2016, International Journal of Endocrinology CrossRef
3. Chemoresistance and chemosensitization in cholangiocarcinoma.
   Jose J G Marin et al, 2018, Biochim Biophys Acta Mol Basis Dis CrossRef
4. null
   Eberhard Schlatter, 2016 CrossRef
5. Association between Polymorphisms of OCT1 and Metabolic Response to Metformin in Women with Polycystic Ovary Syndrome
   Hui Chang et al, 2019, IJMS CrossRef
6. The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy
   Jose JG Marin et al, 2014, Acta Pharmacol Sin CrossRef
7. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
   Jesus M Banales et al, 0 CrossRef
8. null
   Ivan Sabolić et al, 2016 CrossRef
9. Deletion of organic cation transporter Oct3 promotes hepatic fibrosis via upregulation of TGFβ
   Johanna Vollmar et al, 2019, American Journal of Physiology-Gastrointestinal and Liver Physiology CrossRef
10. The Contribution of Human OCT1, OCT3, and CYP3A4 to Nitidine Chloride–Induced Hepatocellular Toxicity
    Liping Li et al, 2014, Drug Metab Dispos CrossRef
11. Organic Cation Transporter–Mediated Clearance of Cardiovascular Drugs
    Omar T. Hassan et al, 2016, American Journal of Therapeutics CrossRef
12. Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT)
    Elisa Lozano et al, 2015, Journal of Controlled Release CrossRef
13. Genetic and/or non-genetic causes for inter-individual and inter-cellular variability in transporter protein expression: implications for understanding drug efficacy and toxicity
    Seok Hwee Koo et al, 2015, Expert Opinion on Drug Metabolism & Toxicology CrossRef
14. Role of transportome in the pharmacogenomics of hepatocellular carcinoma and hepatobiliary cancer
    Marta Alonso-Peña et al, 2019, Pharmacogenomics CrossRef
15. Joint analysis of multiple high-dimensional data types using sparse matrix approximations of rank-1 with applications to ovarian and liver cancer
    Gordon Okimoto et al, 2016, BioData Mining CrossRef
16. The human organic cation transporter OCT1 and its role as a target for drug responses.
    Nicolas Brosseau et al, 2019, Drug Metab Rev CrossRef
17. null
    Xiaodong Liu, 2019 CrossRef
18. Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis
    Johanna Vollmar et al, 2017, Oncotarget CrossRef
19. Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma
    Nerea Urtasun et al, 2017, Oncotarget CrossRef
20. Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
    Jesus M Banales et al, 2020, Nat Rev Gastroenterol Hepatol CrossRef
21. Uptake Transporters of the SLC21, SLC22A, and SLC15A Families in Anticancer Therapy-Modulators of Cellular Entry or Pharmacokinetics?
    Karin Brecht et al, 2020, Cancers (Basel) CrossRef
22. A guide to plasma membrane solute carrier proteins
    Mattia D. Pizzagalli et al, 2020, FEBS J. CrossRef
23. Drug-Drug Interactions at Organic Cation Transporter 1
    Shiwei Zhou et al, 2021, Front. Pharmacol. CrossRef
24. Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1
    Muhammad Erfan Uddin et al, 2021, Front. Pharmacol. CrossRef
25. Expression and clinical significance of organic cation transporter family in glioblastoma multiforme
    Qingbei Lian et al, 2021, Ir J Med Sci CrossRef
26. Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models
    Qingfan Zheng et al, 2022, Front. Oncol. CrossRef
27. Bile duct ligation differently regulates protein expressions of organic cation transporters in intestine, liver and kidney of rats through activation of farnesoid X receptor by cholate and bilirubin
    Shijin Hong et al, 2022, Acta Pharmaceutica Sinica B CrossRef
28. Organic Anion Transporters (OAT) and Other SLC22 Transporters in Progression of Renal Cell Carcinoma
    Thomas C. Whisenant et al, 2022, Cancers CrossRef
29. The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of Tyrosine Kinase Inhibitors
    Fangrui Xiu et al, 2023, IJMS CrossRef
30. The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy
    Elena Puris et al, 2023, Pharmaceutics CrossRef
31. Transcriptome analysis reveals the regulatory effects of Bacillus amyloliquefaciens and Bacillus pumilus on immune and digestive related genes in the spleen of weanling black goats
    Nanchi Zhang et al, 2023, Funct Integr Genomics CrossRef
32. Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors
    Elisa Herraez et al, 2023, Biochemical Pharmacology CrossRef
33. Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition
    Jose J.G. Marin et al, 2024, Biochemical Pharmacology CrossRef
34. In Vitro and In Silico Studies on Cytotoxic Properties of Oxythiamine and 2′-Methylthiamine
    Marta Malinowska et al, 2024, IJMS CrossRef